ResMed Inc. 10-Q Summary: Quarter Ended September 30, 1998
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 1998. ResMed Inc. is a Delaware corporation and holding company for ResMed Holdings Ltd., an Australian entity that designs, manufactures, and markets devices for the evaluation and treatment of sleep-disordered breathing, primarily obstructive sleep apnea. Principal manufacturing is located in Australia, with major distribution and sales sites in the United States, United Kingdom, and Europe.
Key Financial Metrics
| Metric (in thousands) | Q1 1998 | Q1 1997 |
|---|---|---|
| Net Revenue | $19,244 | $13,978 |
| Gross Profit | $13,160 | $8,553 |
| Gross Margin | 68.4% | 61.2% |
| Operating Income | $5,372 | $2,638 |
| Net Income | $3,184 | $2,157 |
| Diluted EPS | $0.42 | $0.29 |
| Cash from Operations | $4,384 | $1,516 |
| Cash & Equivalents (End of Period) | $16,476 | $13,422 |
| Total Debt (Current Loan Payable) | $218 | N/A |
| Working Capital | $32,524 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 38% to $19.2 million, driven primarily by higher unit sales of flow generators and accessories in North and Latin America (up to $11.9 million from $7.0 million).
- Margin Expansion: Gross margin improved to 68% from 61%, attributed to a shift to higher-margin products, production efficiencies, and a decline in the Australian dollar reducing manufacturing costs.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 37% to $6.4 million due to an increase in sales and administrative personnel (from 119 to 169). R&D expenses increased 13% to $1.4 million.
- Other Income/Expense: Net other income turned to a net expense of $541,000 (compared to $656,000 income in 1997) due to foreign currency losses from the devaluation of the Australian dollar and reduced interest income.
- Capital Expenditures: Investing cash outflows increased significantly to $4.0 million (from $1.5 million), primarily for the construction of a new Australian facility and equipment purchases.
Outlook, Risks, and Contingencies
- Legal Proceedings: The Company is engaged in significant patent litigation with Respironics, Inc. in the U.S. and Australia. In the U.S., the court has granted partial summary judgment in favor of Respironics on two of four patents; ResMed intends to appeal. In Australia, the Company faces a claim for approximately $1 million regarding alleged unfair trade practices.
- Market Risk: The Company faces exposure to foreign currency fluctuations, particularly the Australian dollar. It utilizes forward exchange contracts and options to hedge these risks. Notional amounts of foreign currency options totaled approximately $66 million as of September 30, 1998.
- Year 2000 Compliance: The Company is implementing an Oracle Applications Enterprise package to ensure Year 2000 compliance, with estimated costs of $2 million. Management expects all systems to be compliant but notes risks regarding third-party vendors and customers.
- Liquidity: Management anticipates expending approximately $6.0 million over the next six months for the new manufacturing facility and computer systems, funded by operating cash flows.
Investor Verification Checklist
- Verify the status and potential financial impact of the ongoing patent litigation with Respironics, Inc., specifically the appeal of the summary judgment rulings.
- Monitor the progress and cost overruns of the new Australian manufacturing facility construction.
- Assess the effectiveness of foreign currency hedging strategies given the volatility of the Australian dollar.
- Confirm the timeline and budget for Year 2000 compliance implementation.
- Review future revenue growth sustainability in North and Latin America following the 38% quarterly increase.